Implications for Practice: Adapting existing EBIs for new audiences contributes to advancing findings of evidence-based research, ultimately providing nurses and other healthcare providers with important referral options to interventions that may provide useful strategies to improve quality of life and reduce targeted therapyYrelated fatigue.
S urvival in patients with chronic myeloid leukemia (CML) improved considerably after the introduction of the first tyrosine kinase inhibitor (TKI) imatinib. 1 Although TKIs revolutionized treatment of chronic phase CML, they may need to be taken indefinitely and on a daily basis. 2 Accordingly, with the growing use of maintenance therapy in certain forms of cancer, CML has become a chronic condition. The transition from short-term active treatment to potentially lifelong maintenance treatment brings attention to finding ways to manage common side effects such as fatigue and pain. Although evidencebased interventions for managing these side effects are available for cancer patients during or after short-term active treatment, 3, 4 they are not designed for and have not been tested for efficacy in the expanding number of patients who are receiving maintenance treatment with TKIs.
To address the need for an intervention that supports CML patients in managing their health during maintenance TKI treatment, we have built upon a previously empirically supported version of a therapist-delivered cognitive behavioral program for disease-free cancer patients 5 that specifically addresses one of the most common and debilitating side effects, that is, fatigue. In this article, we describe processes used to adapt an existing evidence-based intervention for application in CML patients with targeted therapyYrelated fatigue. Beyond this immediate goal, the current report seeks to illustrate an approach that can be applied to other existing evidence-based interventions for improving the lives of cancer patients.
As background, fatigue proves to be 1 of the 5 most severe side effects in CML patients who are prescribed TKIs, alongside drowsiness, disturbed sleep, muscle soreness and cramping, and trouble remembering things, with one-third of patients reporting persistent moderate to severe symptoms. 6 In addition, compared with age-matched controls with no history of cancer, patients with CML who take a TKI report significantly worse fatigue severity and fatigue interference. 7 Moreover, fatigue is the most important factor that limits quality of life of CML patients. 8 Treatment of fatigue is particularly relevant as chronic side effects may affect adherence to TKI treatment, and adherence is a critical factor to ensure appropriate molecular responses. 9 Despite the acknowledged importance of this symptom, there are no published intervention studies addressing targeted therapyYrelated fatigue. However, previous research has demonstrated the efficacy of cognitive behavior therapy (CBT) designed for treating postcancer fatigue. 5, 10 The conceptual framework for the intervention developed by the Expert Center for Chronic Fatigue (Nijmegen, the Netherlands) is a model that distinguishes factors that precipitate fatigue from factors that perpetuate fatigue. 11 The underlying assumption is that cancer treatment and/or the disease itself may trigger fatigue (precipitating factors), but that other factors such as sleep disturbance, physical inactivity, and fear of disease recurrence are responsible for the persistence of fatigue (perpetuating factors). As such, CBT for postcancer fatigue is a tailored, individualbased, clinic-delivered intervention that itself was adapted from the original CBT for chronic fatigue syndrome developed by the Expert Center for Chronic Fatigue. 12 Cognitive behavior therapy for postcancer fatigue sessions cover 6 possible perpetuating factors (the ''Modules''): Sleep, Activity, Helpful Thinking, Coping With Cancer, Social Support, and Fear of Disease Recurrence (see Table 1 for a description of existing intervention modules). Evidence supports the efficacy of CBT for postcancer fatigue in decreasing severe fatigue and functional impairment. 5, 10 Based on this evidence, it is now among the recommended interventions for addressing fatigue in diseasefree cancer survivors in guidelines issued by the American Society of Clinical Oncology. 13 The current report describes a series of systematic steps and processes to adapt and modify an existing evidence-based intervention in response to the needs of another patient population. The process of modifying an evidence-based intervention without changing the intervention's core elements and internal logic is often referred to as ''adaptation.'' 14 Instead of starting over and expending scarce resources, adapting existing evidence-based interventions has the potential to accelerate the translation of research into practice, thus providing healthcare professionals and patients with treatment options for new patient target groups. The adaptation process allows for changing context in terms of structure, intensity, format, metaphors, goals, and others, while maintaining essential theoretical fidelity and fit. To guide the adaptation process, we developed a plan drawn from the adaptation literature ; and the ADAPT-ITT Model. 26 Table 2 summarizes our plan modeled after the ADAPT-ITT model that includes 8 phases: (1) assessment; (2) decisions on evidence-based intervention selection; (3) administrationVwhat needs to be adapted; (4) production; (5) topical experts; (6) integration; (7) training; and (8) testing. This article focuses primarily on the initial steps and methodologies (1Y6), which provided the necessary foundation for informing the adaptation. The details on the training and specific results of the pilot study (steps 7 and 8), once complete, will be reported in the future.
As described in the upcoming sections, the adaptation process described here represents a series of sequential phases and steps that advance an idea in response to a patient need, to a final testing and evaluation phase. In our case, this adaptation was predicated on the need for an intervention that offered strategies for patients with CML to ameliorate targeted therapyY related fatigue. The adaptation described here also involves moving from a clinic-based face-to-face delivery during a 6-month period (biweekly sessions) to an Internet-assisted delivery format using video telephony and tablet computer technology (ie, FaceTime using iPads) during an 18-week period (weekly sessions) to reduce travel burden. Therefore, as part of our adaptation plan, we also sought to gauge CML patients' interest in, and acceptability of, delivery channel, duration, and frequency of CBT for targeted therapyYrelated fatigue. Our approach builds upon a previously effective evidencebased intervention for postcancer fatigue 5 and an established patient need. 8 We were not proposing to develop a de novo intervention. Rather, the program builds on an existing intervention comprised of 6 modules, based on the precipitatingperpetuating model for fatigued disease-free cancer patients.
5,10
Phase 3VAdministration (What Needed to Be Adapted?)
As part of the adaptation process, we conducted in-depth interviews with CML patients and providers. Next, findings were summarized and implications for adaptation of the existing evidence-based intervention were formulated in close collaboration with topical experts (ie, developers of the original evidencebased intervention). Then, the original therapy manual and training materials were revised through intensive iterative back/ forth communications among research members to incorporate feedback from patients and providers.
Participants and Procedures
Eligible patients were 18 years or older, able to speak and read English, diagnosed with chronic phase CML, not previously treated for other cancer (except nonmelanoma skin cancer) in the past 2 years, under the care of a Moffitt Cancer Center physician, and on a TKI for 3 months or more. In addition, patients had to report moderate-severe fatigue in the past week as reflected by a Fatigue Symptom Inventory score of 4 or higher. 27 Patients were excluded if they had a clinical condition or disease (eg, anemia or multiple sclerosis) that could account for the presence of moderate-severe fatigue. Potential patient participants were identified via review of medical records and appointment schedules by study coordinators. Identified patients were telephoned 1 week before their next appointment to explain study procedures and screened for fatigue. Eligible patients who gave written informed consent were asked to stay after their appointment to be interviewed.
Eligible providers were staff members in the Department of Malignant Hematology at Moffitt Cancer Center who cared for CML patients as a medical doctor, advanced registered nurse practitioner, physician assistant, or registered nurse. Patients with CML at Moffitt Cancer Center are treated by a limited sample of providers. Provider participants were identified and then invited for participation via e-mail. Eligible providers who gave written informed consent were scheduled for an interview.
Instrumentation and Data Collection
Preceding the interview, patients provided demographic information (eg, age, gender, race, ethnicity, marital status, and education) by completing a self-report form. Clinical information (eg, CML diagnosis date, current TKI start date, and previous TKI [if applicable]) was collected via medical chart review.
Patient and provider semistructured interview guides were developed by 2 of the study investigators (P.B.J. and C.D.M.) based on relevant literature, their clinical experiences, and discussion with the topical experts (H.K. and M.F.M.G.). The guides consisted of questions about (1) general thoughts about fatigue in relation to TKIs and CML; (2) general thoughts about TKIs and CML (the provider guide had some additional questions to evaluate the type of education provided to patients before the start of TKI therapy); (3) overall reaction to CBT for targeted therapyYrelated fatigue program; (4) usefulness and ranking of existing modules; (5) other useful topics; and (6) reaction to Internet-assisted delivery channel (ie, FaceTime using iPads), duration, and frequency of CBT for targeted therapyY related fatigue. To help elicit feedback about the existing 6 modules, the interviewers had the modules listed on cards. This made it easier to respond to each module one at a time and gather feedback. It also helped to facilitate ranking of the modules in terms of relative importance. New topics were also solicited.
Two behavioral scientists (P.B.J. and C.D.M.) with extensive interviewing experience conducted the individual interviews with patients and providers using the interview guides. Regarding the sample size for the patient interviews (n = 10), we were guided by the concept of data saturation, which was defined in this study as the point that no new insights or themes were observed. 28 Our research team continually assessed the adequacy of this sample in terms of quality, comprehensiveness, and richness of information. 29 For example, was there sufficient depth of information to adequately inform the adaptation of the evidence-based intervention and at which point were no new insights observed? In addition to the number of interviews, the team also considered the amount of time spent with each CML patient (up to 60 minutes) when defining data saturation and stopping data collection. 30 In terms of healthcare providers, our sample was defined (and somewhat limited) by the existing number of providers (n = 4) at our institution who cared primarily for patients with CML. Albeit small, it was felt that this sample well represented the required perspectives to address potential modifications for the adapted evidence-based intervention. Time spent with providers was approximately 40 minutes. All interviews were audio-recorded and transcribed by a local professional transcriptionist with experience in qualitative health research. Each patient received $50, and each provider received $35 for participating. Liberty Institutional Review Board, a central independent review board, approved the study.
Data Analyses
All interviews were transcribed verbatim. Data transcripts were manually coded using directed content analysis techniques to extend and refine existing theory on CBT for postcancer fatigue to CBT for patients experiencing targeted therapyYrelated fatigue. 31 Codes were generated and refined before and during data analysis using a series of iterative processes by 2 study researchers (H.P. and C.D.M.). First, the researchers created an initial codebook based on a priori (deductive) codes drawn from existing theory, the interview guides, and research questions. The researchers then reviewed all transcripts carefully, highlighting all passages that described relevant data. All highlighted passages were coded using the predetermined codes. Any text that could not be coded into one of these initial codes was given a new inductive code (eg, ''impact of fatigue'' for descriptions of how fatigue impacted areas of daily living). 31 The same researchers independently hand-coded the transcripts, compared codes, and resolved discrepancies through consensus, to reach an optimal inter-rater agreement (95%). 32 The data were summarized through descriptive summaries and data display matrices, in which supportive and expanded views of the existing CBT for postcancer fatigue were identified. A summary listing of module content rankings was also included. The authors reviewed, validated, and verified interpretations, and study conclusions via weekly calls with topical experts. Representative, participant responses were selected to illustrate key findings.
n Results
Of the initial 12 eligible patients who were approached for participation, 1 was found ineligible after consent and 1 declined to be interviewed; consequently, 10 patient interviews were conducted in total. Four providers were approached and consented for participation. The mean age of patient participants was 53 years (range, 37Y70 years), 60% was male, and 70% white/30% African American. Most patients were employed and married and had some college education. The sample included patients with varying disease and treatment durations. Median time since diagnosis was 6.5 years (range, 4 months to 10 years) and median time on current TKI was 11 months (range, 3 months to 6 years). Ninety percent of patients had used at least 1 TKI previously. The most frequently used current TKIs were nilotinib (50%) and dasatinib (40%).
Findings From Patient and Provider Interviews
Illustrative quotations from patients and providers are incorporated in the text in quotes.
THOUGHTS ABOUT PATIENTS' FATIGUE
Patients commonly described fatigue as ''crushing,'' being ''worn out'' or ''whipped out,'' and having ''zero energy'' or feeling ''dead.'' Some patients related that they ''cannot get out of bed in the morning''; others just ''crash at the end of the day.'' Fatigue impacts patients in a number of ways, most significantly seen in the change or reduction in social, family, and physical activities. In general, patients felt that their family members are supportive and understanding. Patients indicated that they do not often bring up fatigue to their providers. Most patients felt their providers think fatigue is a normal side effect of TKIs.
Providers acknowledged fatigue as a common complaint, reported by an estimated 70% or more of their CML patients. As such, most providers usually follow up on this concern by discussing sleep patterns, encouraging physical activity, or changing TKIs when more side effects are present.
THOUGHTS ABOUT PATIENTS' MEDICATION AND CML
A number of general thoughts about CML emerged. Considering that most patients wished they did not have a form of cancer at all; some patients described feeling very fortunate for having this type of cancer because they felt ''It's the best one to have.'' Alternatively, some patients felt guilty for doing well and looking so healthy compared with other patients seen at the cancer center. They stated that they ''don't look sick.'' Most patients experienced a range of side effects from the TKIs (eg, fatigue, nausea, diarrhea, joint pain, and muscle cramp) but related no intentional dose skipping as they felt the TKI is ''keeping me alive'' and is their ''life preserver.'' Unintentional dose skipping was reported by patients, mostly forgetting the second evening dose of nilotinib due to falling asleep. An overwhelming majority of patients clearly attributed their fatigue to the use of TKIs. In fact, only 1 patient did not specifically attribute fatigue to TKI use per se but rationalized the presence of fatigue with other factors (ie, unhealthy diet, low level of physical activity, being overweight, and under stress). In addition, this patient explained that it was difficult to indicate whether the fatigue was related to TKI use because ''I have been on a TKI for so many years and then I am ten years older.'' Providers thought intentional dose skipping due to side effects does occur in a few patients. All providers had the impression that patients attribute their fatigue to TKI use, and they inform patients about fatigue as a known side effect of all TKIs when initiating treatment.
OVERALL REACTION TO CBT FOR TARGETED THERAPYYRELATED FATIGUE
Patients and providers had a positive attitude toward the intervention, thinking it is ''worthwhile,'' ''great,'' ''a very novel approach,'' and would be ''helpful'' for fatigued patients. Several patients stated that ''It is a good idea,'' and 1 patient further elucidated ''If we can help people out that would be very good, fatigue affects everything.'' Overall, patients were highly positive and expressed being interested in and open to actually using the intervention. One patient preferred simply an e-mail with information, not an intensive interaction with a therapist using video-telephony.
USEFULNESS AND RANKING OF THE EXISTING MODULES
Most patients considered all 6 modules highly useful. The module Sleep currently applied to almost all patients, with waking up too early, falling asleep during the day, or not being able to sleep at bedtime being commonly reported. The module Activity applied to all but 1 patient. Patients experienced reduced or fluctuating activity patterns and considered this module highly pertinent. Most patients reported that the module Helpful Thinking about fatigue was not as applicable to them. Some patients did have hopeless thoughts, such as ''There is nothing I can do'' and ''I just need to accept it,'' but these thoughts did not seem to impact their everyday functioning. There were a variety of reactions when patients were asked about the module Coping With Cancer. More than half of the patients had no major concerns, accepting their situation and saying ''It is what it is.'' However, many identified that some thoughts and emotions were triggered before 3-monthly monitoring visits or in case of bad lab results. Reactions from patients who did report concerns ranged from ''Why do I have this disease?'' and ''How would I cope with it if I ever get to the point where it gets really bad'' to struggling with knowing that not taking the TKI would make them feel better but worsen their disease status. A few struggled with integrating the strict medication regimen into daily life. Although most patients indicated already receiving good support, they did consider the module Social Support a useful topic to discuss. A few patients reported changes in social support (eg, people distancing from them) or unpleasant social interactions (eg, being called ''lazy'' when they were just too tired to do things). Most patients did not experience current issues that would be addressed in the module Fear of Disease Recurrence but felt the module could be useful for others. In fact, patients found the term disease recurrence confusing and instead referred to increased disease activity. An explanation for this is that a response evaluation in CML is determined by the value of a molecular marker (called BCR-ABL transcript), instead of determining ''recurrence'' of a solid tumor in patients of the original evidence-based intervention's population. Chronic myeloid leukemia is often considered a slowly progressing disease with long periods of stability. Hence, the terms and language used needed to be edited to better reflect the experience of patients with CML. Even though most patients felt their disease was well controlled and felt that they did not currently need this module, thoughts about increasing disease activity did occur once in a while, mostly triggered by medical appointments or upcoming blood tests. However, some patients worried more about their future health. One patient stated, ''Ever since I was diagnosed, I'm waiting for the other shoe to drop,'' and later on ''For the first couple years I really did feel that, I had maybe a short period of time, I didn't think that I would live that long and so that was a concern and it certainly impacted the way I was living my life.'' Another patient expressed having thoughts about increase in disease activity all the time, especially after the last switch of TKIs, and expressed ''I still have people who depend on me.'' One patient mentioned the scary aspect of ''dying at a young age.'' In summary, most patients felt all the topics were important for inclusion in the intervention, but the highest priority ones were identified as Activity, Sleep, and Coping With Cancer. If any module did not apply to them now, all were open to future discussions.
In all, providers considered the content of the 6 modules useful. One provider did not recognize disrupted sleep/wake patterns as a problematic issue within this patient group. Reactions to the usefulness of the module on fear of disease recurrence (or increased disease activity) varied among the providers. Some providers thought the content of this module would be more helpful for patients that needed to switch TKIs as a result of increased disease activity compared to patients with stable disease. In addition, 1 provider wondered about patients' understanding of treatment response and stated: ''the tests that we use to measure whether they are having a good response are very confusing to patients. It's a lot of technical lingo.'' According to providers, the most relevant topics were Activity, Helpful Thinking, and Sleep/ Coping With Cancer, with the latter 2 topics being ranked equally.
OTHER USEFUL TOPICS
Patients mentioned several suggestions for additional topics, including more information on CML and TKIs, nutrition, and impact of CML and fatigue on personal relationships. Providers considered general information about CML and TKIs potentially useful, suggested support groups for fatigued CML patients, and raised fertility issues in younger patients. Some of these topics may be useful in other patient education venues outside of the current intervention.
REACTIONS TO INTERNET-ASSISTED DELIVERY, DURATION, AND FREQUENCY OF CBT FOR TARGETED THERAPYYRELATED FATIGUE
Overall, patients were very receptive to intervention delivery via video-telephony (ie, FaceTime using iPads). Duration and frequency of CBT for targeted therapyYrelated fatigue (ie, 18 weeks, weekly sessions) were acceptable to patients. All patients were familiar with the Internet; most were daily users. One patient expressed a preference to meet the therapist inperson before starting the Internet-assisted intervention. Providers had some mixed feelings from a technology perspective; it was thought that older patients might be less receptive to the Internet-assisted delivery channel. However, we found no differences in the views of younger and older patients regarding their acceptability and interest in the Internet-assisted delivery channel.
Phases 4, 5, and 6VProduction, Topical Experts, and Integration
Data and information obtained from the interviews were used to draft a creative brief. A creative brief is a well-identified summary/blueprint of findings that helps to inform the adaptation of the intervention. Table 3 displays the summary of interview findings with adaptation implications and was used to guide the modifications. The goal was to create a therapy manual for therapists that described the process of CBT as applied to patients with targeted therapyYrelated fatigue and CML and to provide a description of what should be covered in each module. The research team and topical experts (ie, study consultants who had developed the original evidence-based intervention) then began integrating findings into the therapy manual. The original therapy manual consists of several components: the first section gives an introduction to postcancer fatigue, followed by an explanation of the model of perpetuating factors, a section on diagnostic measures for each perpetuating factor, and separate sections describing the content of each module. The research team and topical experts had weekly conference calls over a 16-week period to examine each component of the original manual to identify areas to modify, delete, or adapt content based on feedback from the patients and providers, for example, replacing ''fear of disease recurrence'' with ''fear of increased disease activity''. In addition, not all existing case vignettes and quotes in the therapy manual (original vignettes were geared toward disease-free cancer patients) were pertinent for CML patients. Therefore, these were replaced with vignettes and quotations derived from the interviews that better reflected & Emphasize to patients that adherence to TKIs is needed during CBT to conclude if CBT for targeted therapyYrelated fatigue is effective, but increasing adherence itself is not a goal of the current intervention. & No implications for adaptation, this is not a part of the current intervention, but may be useful in other patient education venues. Reaction to Internet-assisted delivery, duration, and frequency of CBT for targeted therapyYrelated fatigue & All participants were familiar with using the Internet and receptive to CBT for targeted therapyYrelated fatigue delivery via video telephony.
& Maintain intended use of video telephony (ie, FaceTime) for intervention delivery.
everyday experiences of CML patients. Feedback about the proposed Internet-assisted delivery channel (ie, FaceTime using iPads) from patients and providers was generally positive. Some providers felt that elderly patients might be less receptive to Internet-assisted delivery, but previous studies indicated that elderly (cancer) patients appear to participate readily in Internetassisted self-management programs. 33, 34 Furthermore, no differences were found between younger and older patients in our sample with regard to openness to Internet-assisted intervention delivery, if they were given instructions. Based on discussion with the topical experts and due to a comment by one of the patients, the first intervention session would be delivered in-person to facilitate therapeutic alliance.
Phases 7 and 8VTraining and Testing
Once the therapy manual was finalized, the topical experts created and delivered a 3-day in-person training to prepare 2 therapists for delivering the intervention (H.K. and H.P.). This training included both theoretical background and rationale for each of the intervention modules, familiarizing therapists with intervention delivery, role playing with simulated patients, and discussing video recordings of provider-simulated patients' interactions with feedback from a topical expert. The testing of the Internet-delivered CBT for targeted therapyYrelated fatigue is currently being evaluated in a pilot randomized controlled trial (RCT) conducted to determine if the intervention can effectively reduce fatigue in patients receiving maintenance treatment for CML.
n Discussion
The success of targeted therapy in cancer has improved the overall survival of CML significantly and transformed CML to a chronic disease, yet many patients experience targeted therapyYrelated fatigue. Thus, an Internet-assisted intervention titled ''Cognitive Behavior Therapy for Targeted TherapyY Related Fatigue'' was developed through an adaptation process to address this need. In general, patients and healthcare providers felt that all existing modules were relevant (to varying degrees) and had the potential to improve patients' fatigue while on maintenance TKI treatment.
Our results underscore the importance of a patient-tailored approach of selecting intervention modules. In CBT for targeted therapyYrelated fatigue; therefore, diagnostic assessment instruments will be used to determine which modules should be included and enhanced in the CBT for a particular patient. The CBT will vary only in which modules will be addressed, but within each module, the therapy is standardized. For example, the module on fear of increased disease activity only pertained to a minority subset of patients; as such, not all patients will receive that module as part of the intervention. Furthermore, although the standard term in the literature ''fear of disease recurrence'' typically applies to patients who have completed treatment for early-stage solid malignancies, patients suggested changing this term to ''fear of increased disease activity'', an issue more relevant to patients who are on maintenance treatment to control their disease.
Our study suggested that patients had a need for more information about their disease and treatment. Therefore, the most significant change to the existing therapy manual was the development of a new psychoeducation module ''understanding CML and TKI treatment'' to address this need. This module gauges patients' overall understanding of their disease and treatment, together with a better acceptance of the longterm nature of the treatment needed. An interactive approach was determined to be most suitable for this module. Patients are asked questions about their understanding of CML and its treatment, and the therapist checks or verifies whether this accords with general factual knowledge. Content accuracy was guided by Guidelines Insights for CML from the National Comprehensive Cancer Network, 2 patient information material about CML from the American Cancer Society, 35 and peer-reviewed literature. 36 If patients have further questions, they would be referred to their healthcare provider.
The current study confirmed the utility of using a systematic process for adapting an evidence-based intervention. In particular, the use of the ADAPT-ITT model provided a number of features that allowed for ongoing input from multiple key stakeholders (ie, patients, providers, topical experts, and research team members). However, we note that owing to the nature of the formative research among patients with CML, we interviewed only a relatively small sample of participants from a single comprehensive cancer center. The sample of 4 healthcare providers at 1 institution, albeit limited perspectives, offers an exceedingly important snapshot of the views of nurses and other healthcare providers who primarily care for and are highly familiar with the needs and concerns of patients with CML. In this study, the adaptation process was greatly enriched by the topical experts who had developed the ''original'' evidence-based intervention, and their involvement was a significant strength to the process. Not only was their input essential in the development of the adapted therapy modules and manual, but also their engagement enabled us to train therapists in-person on how to deliver the core elements of the adapted intervention. We have provided further tips in Table 4 , which might be helpful for researchers interested in undertaking similar adaptations of existing evidencebased interventions. Overall, the use of a systematic process for adaptation allowed us to systematically track and pinpoint content areas that should remain the same as well as direct areas to be further customized and modified. Most importantly, it offered the research team a highly fluid and flexible blueprint for documenting the adaptation procedures. 26 Our results provide evidence that CML patients have a need for more information on their disease and treatment. As CML is transforming into a chronic illness, practitioners should be aware that it is important for patients to better understand their disease and the way their response is monitored. This might help patients in better understanding and adjusting to the long-term nature of their treatment. The Internet-assisted delivery channel of the intervention appears to be a suitable and flexible vehicle to disseminate information for CML patients while reducing travel burden. The pilot RCT will be useful to supplement the preliminary findings on acceptability of Internet-assisted intervention delivery reported in this study.
Our results set the stage for the pilot RCT (currently underway) that is evaluating the usability, feasibility, and efficacy of the adapted CBT for targeted therapyYrelated fatigue. Ultimately, if proven effective, this will provide nurses and other healthcare professionals with important referral options to interventions offering practical and patient-tailored strategies to address the most important factor limiting quality of life of CML patients treated with TKIs. In summary, this work provides a strong foundation for addressing a major treatment consequence in the growing population of patients for whom targeted therapies are transforming cancer from a life-threatening to a chronic illness. Upon initiating a project, form a collaborative professional relationship with the original intervention developers and clinicians who have experience with delivering the intervention. Ask them to be part of the team. Adhere to systematic and iterative steps that guide the adaptation process driven by initial need for the intervention through the final testing of the adapted intervention. This provides an adaptation blueprint that endorses relevancy, rigor and meaning. Establish a multidisciplinary team (local, national or international) to ensure inclusion of varied perspectives and who bring content-specific knowledge, methodological, and theoretical expertise. This might include well-versed researchers with backgrounds in psychology, nursing, and education as well as providers who care for the patient group. Include a team member with experience in developing and/or adapting interventions or education programs. Engage key stakeholders such as patient and providers to make adaptations to ensure the ecological validity of the intervention, while still maintaining fidelity to the intervention"s core elements. Maintain a robust and consistent communication plan with study team members to ensure discussions and decisions about adaptation adjustments. Finally, carefully document processes and justify modifications of the intervention protocol to monitor success, and revisions of the adapted components.
